Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.8% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
Capital Group International Focus Equity ETF
CGXU
$6.28B
| $421K | ﹤0.01% |
15,500
+4,700
| +44% | +$119K |
|
|
2927
Alphabet (Google) Class A
GOOGL
$4.59T
| $417K | ﹤0.01% |
2,360
-2,273,440
| -100% | -$372M |
|
2928
Black Diamond Therapeutics
BDTX
$98M
| $414K | ﹤0.01% |
167,100
+87,200
| +109% | +$168K |
|
|
IMA
2929
ImageneBio Inc
IMA
$65.2M
| $414K | ﹤0.01% |
25,738
+1,197
| +5% | +$17.6K |
|
2930
Auburn National Bancorp
AUBN
$91.7M
| $413K | ﹤0.01% |
16,509
+500
| +3% | +$10.5K |
|
2931
CPI Aerostructures
CVU
$65.1M
| $413K | ﹤0.01% |
117,900
-23,100
| -16% | -$74.6K |
|
2932
Verastem
VSTM
$503M
| $409K | ﹤0.01% |
+98,600
| New | +$618K |
|
2933
Cardiff Oncology
CRDF
$71.2M
| $409K | ﹤0.01% |
+129,690
| New | +$396K |
|
2934
Apyx Medical
APYX
$176M
| $408K | ﹤0.01% |
181,395
-20,600
| -10% | -$29K |
|
2935
Precigen
PGEN
$2.34B
| $408K | ﹤0.01% |
287,403
-505,400
| -64% | -$718K |
|
2936
iShares MSCI KLD 400 Social ETF
DSI
$5.44B
| $407K | ﹤0.01% |
3,500
+1,200
| +52% | +$128K |
|
2937
iShares Europe ETF
IEV
$1.67B
| $405K | ﹤0.01% |
6,400
-27,900
| -81% | -$1.69M |
|
2938
GSI Technology
GSIT
$232M
| $404K | ﹤0.01% |
120,109
-16,600
| -12% | -$50.6K |
|
2939
US Global Investors
GROW
$36.5M
| $403K | ﹤0.01% |
155,015
+8,524
| +6% | +$19.1K |
|
2940
Willamette Valley Vineyards
WVVI
$12.8M
| $402K | ﹤0.01% |
72,452
-1,100
| -1% | -$6.42K |
|
2941
Coca-Cola
KO
$374B
| $402K | ﹤0.01% |
5,646
+1,748
| +45% | +$125K |
|
|
SUPX
2942
SuperX AI Technology Ltd
SUPX
$292M
| $401K | ﹤0.01% |
+39,714
| New | +$414K |
|
2943
ProShares Ultra S&P500
SSO
$8.05B
| $401K | ﹤0.01% |
+8,200
| New | +$346K |
|
2944
German American Bancorp
GABC
$1.93B
| $401K | ﹤0.01% |
10,400
-20,949
| -67% | -$788K |
|
|
KZR
2945
DELISTED
Kezar Life Sciences
KZR
| $400K | ﹤0.01% |
87,284
+1,700
| +2% | +$7.29K |
|
2946
loanDepot
LDI
$580M
| $400K | ﹤0.01% |
314,600
-138,800
| -31% | -$170K |
|
2947
RAVE Restaurant Group
RAVE
$46.6M
| $398K | ﹤0.01% |
144,758
+11,300
| +8% | +$28.5K |
|
2948
Align Technology
ALGN
$12.3B
| $398K | ﹤0.01% |
+2,100
| New | +$371K |
|
|
CLSD
2949
DELISTED
Clearside Biomedical
CLSD
| $397K | ﹤0.01% |
33,106
-3,861
| -10% | -$47.9K |
|
|
TTAM
2950
Titan America SA
TTAM
$2.9B
| $396K | ﹤0.01% |
+31,700
| New | +$420K |
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.